Next Article in Journal
Does a High-Risk (>1/50) Result for First-Trimester Combined Screening Always Entail Invasive Testing? Which Patients from This Group Might Benefit from cfDNA Testing?
Next Article in Special Issue
Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
Previous Article in Journal
Unusual Mathematical Approaches Untangle Nervous Dynamics
Previous Article in Special Issue
High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma
 
 
Review

Article Versions Notes

Biomedicines 2022, 10(10), 2583; https://doi.org/10.3390/biomedicines10102583
Action Date Notes Link
article xml file uploaded 14 October 2022 16:01 CEST Original file -
article xml uploaded. 14 October 2022 16:01 CEST Update -
article pdf uploaded. 14 October 2022 16:01 CEST Version of Record https://www.mdpi.com/2227-9059/10/10/2583/pdf-vor
article html file updated 14 October 2022 16:02 CEST Original file -
article xml file uploaded 18 October 2022 10:39 CEST Update -
article xml uploaded. 18 October 2022 10:39 CEST Update https://www.mdpi.com/2227-9059/10/10/2583/xml
article pdf uploaded. 18 October 2022 10:39 CEST Updated version of record https://www.mdpi.com/2227-9059/10/10/2583/pdf
article html file updated 18 October 2022 10:40 CEST Update -
article html file updated 28 February 2023 18:11 CET Update -
article html file updated 1 March 2023 21:49 CET Update https://www.mdpi.com/2227-9059/10/10/2583/html
Back to TopTop